INMB RSI Chart
Last 7 days
7.9%
Last 30 days
28.2%
Last 90 days
-22.8%
Trailing 12 Months
50.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 131.0K | 0 | 0 | 0 |
2023 | 249.0K | 279.0K | 224.0K | 155.0K |
2022 | 340.0K | 356.0K | 440.0K | 374.0K |
2021 | 53.5K | 96.0K | 138.5K | 181.0K |
2020 | 0 | 0 | 0 | 11.0K |
2019 | 0 | 0 | 0 | 0 |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Apr 19, 2024 | lowdell mark william | bought | 119,999 | 8.32 | 14,423 | chief scientific officer |
Apr 19, 2024 | moss david j | acquired | 149,993 | 8.32 | 18,028 | cfo, treasurer & secretary |
Apr 19, 2024 | moss david j | bought | 149,993 | 8.32 | 18,028 | cfo, treasurer & secretary |
Apr 19, 2024 | lowdell mark william | acquired | 119,999 | 8.32 | 14,423 | chief scientific officer |
Apr 19, 2024 | juda scott | bought | 246,297 | 8.32 | 29,603 | - |
Apr 19, 2024 | tesi raymond joseph | bought | 149,993 | 8.32 | 18,028 | president and ceo |
Apr 19, 2024 | tesi raymond joseph | acquired | 149,993 | 8.32 | 18,028 | president and ceo |
Apr 19, 2024 | juda scott | acquired | 246,297 | 8.32 | 29,603 | - |
Nov 10, 2023 | juda scott | bought | 48,650 | 6.95 | 7,000 | - |
Jul 12, 2023 | schroeder timothy j | sold | -110,085 | 11.0085 | -10,000 | - |
Which funds bought or sold INMB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | added | 71.49 | 383,458 | 869,147 | -% |
May 15, 2024 | Royal Bank of Canada | added | 43.16 | 322,000 | 973,000 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -99.91 | -380,809 | 353 | -% |
May 15, 2024 | DEUTSCHE BANK AG\ | unchanged | - | 53,826 | 1,290,710 | -% |
May 15, 2024 | Laird Norton Wetherby Trust Company, LLC | unchanged | - | 15,435 | 370,125 | 0.05% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -37.86 | -55,865 | 103,024 | -% |
May 15, 2024 | Federation des caisses Desjardins du Quebec | new | - | 9,400 | 9,400 | -% |
May 15, 2024 | STATE STREET CORP | unchanged | - | 22,081 | 529,490 | -% |
May 15, 2024 | MORGAN STANLEY | added | 114 | 178,717 | 322,879 | -% |
May 15, 2024 | Point72 Asia (Singapore) Pte. Ltd. | new | - | 157,897 | 157,897 | 0.04% |
Unveiling Inmune Bio Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Inmune Bio Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Inmune Bio Inc News
Income Statement (Quarterly) | ||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2019Q2 |
Revenue | -50.0% | 14.00 | 28.00 | 43.00 | 46.00 | 38.00 | 97.00 | 98.00 | 16.00 | 163 | 163 | 14.00 | - | 4.00 | 20.00 | 36.00 |
Operating Expenses | 31.2% | 11,031 | 8,407 | 8,571 | 6,457 | 6,461 | 5,739 | 7,541 | 6,404 | 6,641 | 9,193 | 9,035 | 6,554 | 4,552 | 3,220 | 428 |
S&GA Expenses | -100.0% | - | 2,400 | 2,586 | 2,309 | 2,328 | 2,329 | 2,382 | 2,215 | 2,332 | 2,125 | 2,515 | 2,090 | 2,061 | 1,361 | 1,336 |
R&D Expenses | 44.7% | 8,693 | 6,007 | 5,985 | 4,148 | 4,133 | 3,410 | 5,159 | 4,189 | 4,309 | 7,068 | 6,520 | 4,464 | 2,491 | 1,859 | 635 |
Interest Expenses | -21.4% | 302 | 384 | 464 | 480 | 450 | 410 | 361 | 310 | 291 | 294 | 265 | - | - | - | - |
Income Taxes | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -31.1% | -11,025 | -8,408 | -8,563 | -6,501 | -6,536 | -5,833 | -7,725 | -6,838 | -6,903 | -9,671 | -9,458 | -6,655 | -4,556 | -3,204 | -392 |
Net Income Margin | -36.0% | -263.34* | -193.60* | -122.47* | -95.32* | -108.16* | -72.99* | -70.77* | -92.33* | -96.14* | -167.62* | -172.37* | -199.29* | -272.62* | - | - |
Free Cashflow | -119.8% | -7,476 | -3,401 | -4,264 | -3,174 | -1,141 | -5,695 | -3,367 | -4,759 | -8,865 | -9,780 | -7,923 | -5,709 | -5,092 | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -17.8% | 47.00 | 57.00 | 63.00 | 70.00 | 74.00 | 82.00 | 84.00 | 88.00 | 94.00 | 100 | 108 | 61.00 | 66.00 | 41.00 | 43.00 | 23.00 | 24.00 | 24.00 | 25.00 | 28.00 | 24.00 |
Current Assets | -25.3% | 30.00 | 40.00 | 46.00 | 53.00 | 57.00 | 65.00 | 67.00 | 71.00 | 77.00 | 83.00 | 91.00 | 44.00 | 49.00 | 24.00 | 26.00 | 6.00 | 7.00 | 8.00 | 9.00 | 11.00 | 7.00 |
Cash Equivalents | -27.5% | 26.00 | 36.00 | 42.00 | 48.00 | 51.00 | 52.00 | 57.00 | 61.00 | 67.00 | 75.00 | 84.00 | 40.00 | 45.00 | 22.00 | 24.00 | 5.00 | 6.00 | 7.00 | 7.00 | 9.00 | 6.00 |
Liabilities | -5.6% | 18.00 | 19.00 | 18.00 | 19.00 | 19.00 | 22.00 | 20.00 | 18.00 | 19.00 | 20.00 | 19.00 | 17.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Current Liabilities | -5.5% | 17.00 | 18.00 | 14.00 | 13.00 | 10.00 | 11.00 | 7.00 | 2.00 | 3.00 | 4.00 | 5.00 | 3.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | - |
LT Debt, Current | -24.9% | 7.00 | 10.00 | - | - | - | 5.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholder's Equity | -24.4% | 28.00 | 37.00 | 44.00 | 51.00 | 55.00 | 60.00 | 64.00 | 70.00 | 76.00 | 80.00 | 88.00 | 43.00 | 64.00 | 39.00 | 41.00 | 22.00 | 22.00 | 24.00 | 25.00 | 27.00 | 23.00 |
Retained Earnings | -9.1% | -132 | -121 | -112 | -104 | -97.55 | -91.00 | -85.18 | -77.46 | -70.62 | -63.71 | -54.04 | -44.59 | -37.93 | -33.37 | -30.17 | -25.45 | -23.35 | -21.28 | -18.96 | -15.89 | -15.50 |
Additional Paid-In Capital | 1.1% | 161 | 159 | 157 | 155 | 154 | 152 | 150 | 148 | 146 | 144 | 142 | 88.00 | 101 | 72.00 | 71.00 | 47.00 | 46.00 | 45.00 | 44.00 | 43.00 | 34.00 |
Shares Outstanding | 0.4% | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 18.00 | 17.00 | 15.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 106 | - | - | - | 103 | - | - | - | 157 | - | - | - | 0.00 | - | - | - | 35.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -119.8% | -7,476 | -3,401 | -4,264 | -3,174 | -1,141 | -5,695 | -3,367 | -4,759 | -8,865 | -9,780 | -7,923 | -5,709 | -5,092 | -2,392 | -3,698 | -1,818 | -1,035 | -433 | -1,945 | -1,617 | -1,387 |
Share Based Compensation | -5.3% | 1,779 | 1,879 | 1,889 | 1,863 | 1,737 | 1,788 | 1,939 | 1,886 | 1,536 | 1,522 | 1,606 | 769 | 899 | 703 | 1,046 | 682 | 682 | 1,172 | 975 | 975 | 975 |
Cashflow From Investing | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cashflow From Financing | 0% | -2,500 | -2,500 | - | - | - | - | - | - | 729 | - | 52,942 | 14,951 | 28,464 | - | 23,240 | 664 | -9.00 | - | - | 4,958 | 7,251 |
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
REVENUE | $ 14 | $ 38 |
OPERATING EXPENSES | ||
General and administrative | 2,338 | 2,328 |
Research and development | 8,693 | 4,133 |
Total operating expenses | 11,031 | 6,461 |
LOSS FROM OPERATIONS | (11,017) | (6,423) |
OTHER EXPENSE, NET | (8) | (113) |
NET LOSS | $ (11,025) | $ (6,536) |
Net loss per common share – basic (in Dollars per share) | $ (0.61) | $ (0.36) |
Weighted average common shares outstanding – basic (in Shares) | 18,026,473 | 17,945,995 |
COMPREHENSIVE LOSS | ||
Net loss | $ (11,025) | $ (6,536) |
Other comprehensive income (loss) – foreign currency translation | 130 | (9) |
Total comprehensive loss | $ (10,895) | $ (6,545) |
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
CURRENT ASSETS | ||
Cash and cash equivalents | $ 26,002 | $ 35,848 |
Research and development tax credit receivable | 2,133 | 1,905 |
Other tax receivable | 557 | 537 |
Prepaid expenses and other current assets | 1,109 | 1,510 |
TOTAL CURRENT ASSETS | 29,824 | 39,942 |
Operating lease – right of use asset | 389 | 414 |
Other assets | 106 | 131 |
Acquired in-process research and development intangible assets | 16,514 | 16,514 |
TOTAL ASSETS | 46,833 | 57,001 |
CURRENT LIABILITIES | ||
Accounts payable and accrued liabilities | 9,294 | 7,901 |
Deferred liabilities | 520 | 489 |
Current portion of long-term debt | 7,455 | 9,921 |
Operating lease, current liabilities | 125 | 119 |
TOTAL CURRENT LIABILITIES | 17,450 | 18,465 |
Long-term operating lease liability | 360 | 397 |
TOTAL LIABILITIES | 17,810 | 18,862 |
COMMITMENTS AND CONTINGENCIES | ||
Redeemable common stock, $0.001 par value; 75,697 issued and outstanding, respectively (Note 9) | 799 | 799 |
STOCKHOLDERS’ EQUITY | ||
Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding | ||
Common stock, $0.001 par value, 200,000,000 shares authorized, 17,950,776 shares issued and outstanding, respectively | 18 | 18 |
Additional paid-in capital | 160,922 | 159,143 |
Accumulated other comprehensive loss | (669) | (799) |
Accumulated deficit | (132,047) | (121,022) |
TOTAL STOCKHOLDERS’ EQUITY | 28,224 | 37,340 |
TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY | 46,833 | 57,001 |
Related Party | ||
CURRENT ASSETS | ||
Prepaid expenses – related party | 23 | 142 |
CURRENT LIABILITIES | ||
Accounts payable and accrued liabilities – related parties | $ 56 | $ 35 |